Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography

Michael J. Glantz, John M. Hoffman, R. Edward Coleman, Allan H. Friedman, Michael W. Hanson, Peter C. Burger, James E. Herndon PhD, William J. Meisler, S. Clifford Schold

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

As aggressive neurosurgery and adjuvant therapy have become standard care for most patients with primary central nervous system (CNS) tumors, limitations of posttreatment neuroimaging techniques have become more apparent. Interpretation of computed cranial tomography (CT) and magnetic resonance imaging (MRI) in patients with brain tumors is complicated by changes related to surgery, corticosteroids, radiation, and chemotherapy. We investigated the role of 18F‐2‐fluoro‐2‐deoxy‐D‐glucose (FDG) positron emission tomography (FDG‐PET) in these difficult diagnostic situations by obtaining FDG‐PET scans in 5 patients following temporal lobectomy for epilepsy, in 5 patients with recurrent anaplastic gliomas before and after corticosteroid therapy, and in 5 patients after the development of histologically confirmed radionecrosis. We also obtained postoperative FDG‐PET scans in 32 consecutive patients undergoing initial resection of a primary brain tumor. Our results indicate that glucose uptake as detected by FDG‐PET scanning with[18F]fluorodeoxyglucose is not increased in the postoperative period; is not affected by steroid therapy; and accurately predicts early recurrence of tumor, supplementing other predictors of tumor behavior, including extent of resection, histological diagnosis, and postoperative CT. Thus PET using [18F] fluorodeoxyglucose can contribute to the optimum management of patients with primary brain tumors.

Original languageEnglish (US)
Pages (from-to)347-355
Number of pages9
JournalAnnals of Neurology
Volume29
Issue number4
DOIs
StatePublished - Apr 1991

Fingerprint

Central Nervous System Neoplasms
Fluorodeoxyglucose F18
Positron-Emission Tomography
Recurrence
Brain Neoplasms
Adrenal Cortex Hormones
Tomography
Neurosurgery
Postoperative Period
Neuroimaging
Glioma
Epilepsy
Neoplasms
Patient Care
Therapeutics
Steroids
Magnetic Resonance Imaging
Radiation
Glucose
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Glantz, Michael J. ; Hoffman, John M. ; Coleman, R. Edward ; Friedman, Allan H. ; Hanson, Michael W. ; Burger, Peter C. ; Herndon PhD, James E. ; Meisler, William J. ; Schold, S. Clifford. / Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. In: Annals of Neurology. 1991 ; Vol. 29, No. 4. pp. 347-355.
@article{f6b85ad63ee8434b8db34d5384d6f40d,
title = "Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography",
abstract = "As aggressive neurosurgery and adjuvant therapy have become standard care for most patients with primary central nervous system (CNS) tumors, limitations of posttreatment neuroimaging techniques have become more apparent. Interpretation of computed cranial tomography (CT) and magnetic resonance imaging (MRI) in patients with brain tumors is complicated by changes related to surgery, corticosteroids, radiation, and chemotherapy. We investigated the role of 18F‐2‐fluoro‐2‐deoxy‐D‐glucose (FDG) positron emission tomography (FDG‐PET) in these difficult diagnostic situations by obtaining FDG‐PET scans in 5 patients following temporal lobectomy for epilepsy, in 5 patients with recurrent anaplastic gliomas before and after corticosteroid therapy, and in 5 patients after the development of histologically confirmed radionecrosis. We also obtained postoperative FDG‐PET scans in 32 consecutive patients undergoing initial resection of a primary brain tumor. Our results indicate that glucose uptake as detected by FDG‐PET scanning with[18F]fluorodeoxyglucose is not increased in the postoperative period; is not affected by steroid therapy; and accurately predicts early recurrence of tumor, supplementing other predictors of tumor behavior, including extent of resection, histological diagnosis, and postoperative CT. Thus PET using [18F] fluorodeoxyglucose can contribute to the optimum management of patients with primary brain tumors.",
author = "Glantz, {Michael J.} and Hoffman, {John M.} and Coleman, {R. Edward} and Friedman, {Allan H.} and Hanson, {Michael W.} and Burger, {Peter C.} and {Herndon PhD}, {James E.} and Meisler, {William J.} and Schold, {S. Clifford}",
year = "1991",
month = "4",
doi = "10.1002/ana.410290403",
language = "English (US)",
volume = "29",
pages = "347--355",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

Glantz, MJ, Hoffman, JM, Coleman, RE, Friedman, AH, Hanson, MW, Burger, PC, Herndon PhD, JE, Meisler, WJ & Schold, SC 1991, 'Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography', Annals of Neurology, vol. 29, no. 4, pp. 347-355. https://doi.org/10.1002/ana.410290403

Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. / Glantz, Michael J.; Hoffman, John M.; Coleman, R. Edward; Friedman, Allan H.; Hanson, Michael W.; Burger, Peter C.; Herndon PhD, James E.; Meisler, William J.; Schold, S. Clifford.

In: Annals of Neurology, Vol. 29, No. 4, 04.1991, p. 347-355.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography

AU - Glantz, Michael J.

AU - Hoffman, John M.

AU - Coleman, R. Edward

AU - Friedman, Allan H.

AU - Hanson, Michael W.

AU - Burger, Peter C.

AU - Herndon PhD, James E.

AU - Meisler, William J.

AU - Schold, S. Clifford

PY - 1991/4

Y1 - 1991/4

N2 - As aggressive neurosurgery and adjuvant therapy have become standard care for most patients with primary central nervous system (CNS) tumors, limitations of posttreatment neuroimaging techniques have become more apparent. Interpretation of computed cranial tomography (CT) and magnetic resonance imaging (MRI) in patients with brain tumors is complicated by changes related to surgery, corticosteroids, radiation, and chemotherapy. We investigated the role of 18F‐2‐fluoro‐2‐deoxy‐D‐glucose (FDG) positron emission tomography (FDG‐PET) in these difficult diagnostic situations by obtaining FDG‐PET scans in 5 patients following temporal lobectomy for epilepsy, in 5 patients with recurrent anaplastic gliomas before and after corticosteroid therapy, and in 5 patients after the development of histologically confirmed radionecrosis. We also obtained postoperative FDG‐PET scans in 32 consecutive patients undergoing initial resection of a primary brain tumor. Our results indicate that glucose uptake as detected by FDG‐PET scanning with[18F]fluorodeoxyglucose is not increased in the postoperative period; is not affected by steroid therapy; and accurately predicts early recurrence of tumor, supplementing other predictors of tumor behavior, including extent of resection, histological diagnosis, and postoperative CT. Thus PET using [18F] fluorodeoxyglucose can contribute to the optimum management of patients with primary brain tumors.

AB - As aggressive neurosurgery and adjuvant therapy have become standard care for most patients with primary central nervous system (CNS) tumors, limitations of posttreatment neuroimaging techniques have become more apparent. Interpretation of computed cranial tomography (CT) and magnetic resonance imaging (MRI) in patients with brain tumors is complicated by changes related to surgery, corticosteroids, radiation, and chemotherapy. We investigated the role of 18F‐2‐fluoro‐2‐deoxy‐D‐glucose (FDG) positron emission tomography (FDG‐PET) in these difficult diagnostic situations by obtaining FDG‐PET scans in 5 patients following temporal lobectomy for epilepsy, in 5 patients with recurrent anaplastic gliomas before and after corticosteroid therapy, and in 5 patients after the development of histologically confirmed radionecrosis. We also obtained postoperative FDG‐PET scans in 32 consecutive patients undergoing initial resection of a primary brain tumor. Our results indicate that glucose uptake as detected by FDG‐PET scanning with[18F]fluorodeoxyglucose is not increased in the postoperative period; is not affected by steroid therapy; and accurately predicts early recurrence of tumor, supplementing other predictors of tumor behavior, including extent of resection, histological diagnosis, and postoperative CT. Thus PET using [18F] fluorodeoxyglucose can contribute to the optimum management of patients with primary brain tumors.

UR - http://www.scopus.com/inward/record.url?scp=0025794065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025794065&partnerID=8YFLogxK

U2 - 10.1002/ana.410290403

DO - 10.1002/ana.410290403

M3 - Article

C2 - 1929205

AN - SCOPUS:0025794065

VL - 29

SP - 347

EP - 355

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 4

ER -